Gut Peptide Hormones and Pediatric Type 1 Diabetes Mellitus

M. HUML; J. KOBR; K. Siala; J. VARVAŘOVSKÁ; R. POMAHAČOVÁ; M. KARLÍKOVÁ; J. SÝKORA

doi:10.33549/physiolres.931995

journal article Aug 17, 2011

Gut Peptide Hormones and Pediatric Type 1 Diabetes Mellitus

M. HUML J. KOBR K. Siala

J. VARVAŘOVSKÁ R. POMAHAČOVÁ M. KARLÍKOVÁ J. SÝKORA

Physiological Research pp. 647-658 · Institute of Physiology of the Czech Academy of Sciences

View at Publisher Save 10.33549/physiolres.931995

Abstract

The aims of our study were to evaluate plasma levels of gut hormones in children with Type 1 diabetes mellitus (T1DM) in comparison with healthy controls and to correlate plasma concentrations of gut hormones with blood biochemistry, markers of metabolic control and with anthropometric parameters. We measured postprandial levels of specific gut peptide hormones in T1DM children. Amylin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), ghrelin, leptin, pancreatic polypeptide (PP), and polypeptide YY (PYY) were assessed in 19 T1DM children and 21 healthy reference controls. Multiplex assay kit (LINCOplex®) was used for determination of the defined plasma hormone levels. T1DM subjects had significantly reduced amylin (p<0.001) and ghrelin (p<0.05) levels, whereas GIP (p<0.05) was elevated when compared with healthy controls. Plasma levels of other measured hormones did not differ statistically between the studied groups. Further analysis of T1DM patients demonstrated an association between body mass index and GLP-1 (r=0.4642; p<0.05), leptin (r=0.5151; p<0.05), and amylin (r=0.5193; p<0.05). Ghrelin levels positively correlated with serum HDL cholesterol (r=0.4760; p<0.05). An inverse correlation was demonstrated with triglycerides (TG) (r=-0.5674; p<0.01), insulin dosage (r= -0.5366; p<0.05), and HbA1c% (r= -0.6864; p<0.01). Leptin was inversely correlated with TG (r= -0.6351; p<0.01). Stepwise regression analysis was performed to enlighten the predictive variables. Our study demonstrated an altered secretion pattern of gut peptide hormones in T1DM children. A close correlation was revealed between these peptides as well as with blood biochemistry, markers of metabolic control and with anthropometric parameters. Further studies are essential to explore this issue in T1DM children.

Topics

No keywords indexed for this article. Browse by subject →

References

56

[1]

ADKINSON MA, MACLAREN NK: The Pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1, 1994. 10.1056/nejm199411243312107

[2]

ADRIAN TE, BLOOM SR, BRYANT MG, POLAK JM, HEITZ PH, BARNES AJ: Distribution and release of human pancreatic polypeptide. Gut 17: 940-944, 1976. 10.1136/gut.17.12.940

[3]

BADMAN MK, SHENNAN KI, JERMANY JL, DOCHERTY K, CLARK A: Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378: 227-231, 1997. 10.1016/0014-5793(95)01460-8

[4]

BATTERHAM RL, BLOOM SR: The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci 994: 162-168, 2003. 10.1111/j.1749-6632.2003.tb03176.x

[5]

BERTI L, KELLERER M, CAPP E, HÄRING HU: Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a PI3-kinase mediated effect. Diabetologia 40: 606-609, 1997. 10.1007/s001250050722

[6]

BRAZG RL, BIERMAN EL: Insulin excess counteracts the effects of HDL on intracellular sterol accumulation. Diabetologia 36: 942-947, 1993. 10.1007/bf02374477

[7]

BROGLIO F, PRODAM F, ME E, RIGANTI F, LUCATELLO B, GRANNATA R, BENSO A, GHICO E: Ghrelin: Endocrine, metabolic and cardiovascular actions. J Endocrinol Invest 28: 23-25, 2005.

[8]

BRUNICARDI FC, CHAIKEN RL, RYAN AS: Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 81: 3566-3572, 1996. 10.1210/jc.81.10.3566

[9]

CELI F, BINI V, PAPI F, SANTILLI E, FERRETTI A, MENCACCI M, BERIOLI M, GIORGI DE, FARLONI A: Circulating acylated and total ghrelin andgalanin in childrenwith insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development. Clin Endocrinol 63: 139-145, 2005. 10.1111/j.1365-2265.2005.02313.x

[10]

COURI CEB, FOSS-FREITAS MA, FOSS MC, VOLTARELLI CJ: β-cell regeneration to treat Type 1 diabetes mellitus. Expert Rev Endocrinol Metabol 3: 51-60, 2008. 10.1586/17446651.3.1.51

[11]

CREUTZFELDT W, ORSKOV C, KLEINE N, HOLST JJ, WILLMS B, NAUCK MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19: 580-586, 1996. 10.2337/diacare.19.6.580

[12]

CUMMINGS DE, PURNELL JQ, FRAYO RS, SCHMIDOVA K, WISSE BE, WEIGLE DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719, 2001. 10.2337/diabetes.50.8.1714

[13]

DE LUIS DA, GONZALEZ SAGRADO M, CONDE R, ALLER R, IZAOLA O: Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab 51: 134-138, 2007. 10.1159/000103273

[14]

DEZAKI K, SONE H, YADA T: Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 118: 239-249, 2008. 10.1016/j.pharmthera.2008.02.008

[15]

DOYLE ME, EGAN JM: Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546-593, 2007. 10.1016/j.pharmthera.2006.11.007

[16]

EDELMAN S, MAIER H, WILHELM K: Pramlintide in the treatment of diabetes mellitus. Biodrugs 22: 375-386, 2008. 10.2165/0063030-200822060-00004

[17]

ELDEMAN S, CARG S, FRIAS J, MAGGS D, WANG Y, ZHANG B, STROBEL S, LUTZ K, KOLTERMAN O: A double-blind, placebo controlled trial assessing pram lintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29: 2189-2195, 2006. 10.2337/dc06-0042

[18]

EL-SALHY M, SITOHY B: Abnormal gastrointestinal endocrine cells in patients with diabetes type 1: Relationship to Gastric Emptying. Scand J Gastroenterol 36: 1162-1169, 2001. 10.1080/00365520152584789

[19]

FEENER EP, DZAU FJ: Pathophysiology and treatment of lipid disorders in diabetes. In: Jostlin`s Diabetes Mellitus. 14st Ed. Lippincott Williams & Wilkins, Philadelphia, 2004, pp 874-876.

[20]

GREENBAUM CJ, PRIGEON RL, D’ALESSIO DA: Impaired β-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 51: 951-957, 2002. 10.2337/diabetes.51.4.951

[21]

HASSAN K, HEPTULLA RA: Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. Pediatr Diabetes 10: 264-268, 2009. 10.1111/j.1399-5448.2008.00490.x

[22]

HAZELWOOD RL, TURNER SD, KIMMEL JR, POLLACK HG: Spectrum effects of a new polypeptide (Third Hormone?) isolated from the chicken pancreas. Gen Comp Endocrinol 21: 485-497, 1973. 10.1016/0016-6480(73)90109-3

[23]

HEPTULLA RA, RODRIGUEZ LM, BOMGAARS L, HAYMOND MW: The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 54: 1100-1107, 2005. 10.2337/diabetes.54.4.1100

[24]

HEPTULLA RA, RODRIGUEZ LM, KIMBERLY JM, HAYMOND MW: Gastric emptying and postprandial glucose excursions in adolescents with type 1 diabetes. Pediatr Diabetes 9: 561-566, 2008. 10.1111/j.1399-5448.2008.00430.x

[25]

HOLDSTOCK C, LUDVIGSSON J, KARLSSON FA: Abnormal ghrelin secretion in new onset childhood type 1 diabetes. Diabetologia 47: 150-151, 2004. 10.1007/s00125-003-1258-6

[26]

KIESS W, ANIL M, BLUM WF, ENGLARO P, JUUL A, ATTANASIO A, DÖTSCH J, RASCHER W: Serum leptin levels in children and adolescents with insulin-dependent diabetes mellitus in relation to metabolic control and body mass index. Eur J Endocrinol 138: 501-509, 1998. 10.1530/eje.0.1380501

[27]

KIESS W, KAPELLEN T, SIEBLER T, DOST A, DEUTSCHER J, NIETZSCHMANN U: Improvements and new potentials in pharmacological therapy of diabetes mellitus in children and adolescents. Horm Res 50: 87-90, 1998. 10.1159/000053111

[28]

KONG MF: Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40: 82-88, 1997. 10.1007/s001250050646

[29]

KONO T, HANAZAKI K, YAZAWA K, ASHIZAWA S, FISHER WE, WANG XP, NOSÉ Y, BRUNICARDI FC: Pancreatic polypeptide administration reduces insulin requirements of artificial pancreas in pancreatectomized dogs. Artif Organs 29: 83-87, 2005. 10.1111/j.1525-1594.2004.29008.x

[30]

KRARUP T, MADSBAD S, MOODY AJ: Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent.) diabetes mellitus. J Clin Endocrinol Metab 60: 120-125, 1985. 10.1210/jcem-60-1-120

[31]

KRARUP T, MADSBAD S, MOODY AJ: Gastric inhibitory polypeptide in newly diagnosed ketotic type I (insulin-dependent) diabetics. Acta Med Scand 223: 437-441, 1988. 10.1111/j.0954-6820.1988.tb15895.x

[32]

LYNN FC, NATHALIE P, EDDY HC, CHRISTOPHER HS, MCINTOSH, KIEFFER TJ, PEDERSON RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50: 1004-1011, 2001. 10.2337/diabetes.50.5.1004

[33]

MANNON P, TAYLOR I: The pancreatic polypeptide family. In: Gut Peptides: Biochemistry and Physiology. WALSH B, DOCKRAY G (eds), Raven Press, New York, 1994, pp 351-358.

[34]

MARTOS-MORENO GA, BARRIOS V, SORIANO-GUILLÉN L, ARGENTE J: Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetesmellitus type 1 at diagnosis and after insulin treatment. Eur J Endocrinol 155: 757-761, 2006. 10.1530/eje.1.02273

[35]

MIX H, WIDJABAB A, JANDLA O, CORNBERGA M: Expression of leptin and leptin receptor isoforms in the human stomach. Gut 47: 481-486, 2000. 10.1136/gut.47.4.481

[36]

ORCI L, BAETENS D, RAVAZZOLA M, STEFAN Y, MALAISSE-LAGAE F: Pancreatic polypeptide and glucagon: non-random distribution in pancreatic islets. Life Sci 19: 1811-1815, 1976. 10.1016/0024-3205(76)90112-0

[37]

PANAGIOTIDIS GA: Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glukose in the mouse. Diabetes Res Clin Pract 18: 167-171, 1992. 10.1016/0168-8227(92)90142-e

[38]

PÉREZ C, FERNÁNDEZ-GALAZ C, FERNÁNDEZ-AGULLÓ T, PÉREZ C, FERNÁNDEZ-GALAZ C, FERNÁNDEZ-AGULLÓ T, ARRIBAS C, ANDRÉS A, ROS M, CARRASCOSA JM: Leptin impairs insulin signaling in rat adipocytes. Diabetes 53: 347-353, 2004. 10.2337/diabetes.53.2.347

[39]

POLAK JM, BLOOM SR, ADRIAN TE, HEITZ P, BRYANT MG, PEARSE AGE: Pancreatic polypeptide in insulinomas, gastrinomas, vipomas and glucagonomas. Lancet 1: 328-330, 1976. 10.1016/s0140-6736(76)90084-2

[40]

RANGANATH L, SEDGWICK I, MORGAN L, WRIGHT J, MARKS V: The ageing entero-insular axis. Diabetologia 411: 309-313, 1998. 10.1007/s001250051070

[41]

RANGANATHAN S, CIARALDI TP, HENRY RR, MUDALIAR S, KERN PA: Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells. Endocrinology 139: 2509-2513, 1998. 10.1210/endo.139.5.5980

[42]

RATNER RE, DICKEY R, FINEMAN M, MAGGS DG, SHEN L, STROBEL SA, WEYER C, KOLTERMAN OG: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 21: 1204-1212, 2004. 10.1111/j.1464-5491.2004.01319.x

[43]

RINDI G, TORSELLO A, LOCATELLI V, SOLC E: Ghrelin expression and actions: a novel peptide for an old cell type of the diffuse endocrine system. Exp Biol Med 229: 1007-1016, 2004. 10.1177/153537020422901004

[44]

ROSS SA, DUPRE J: Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on response to intravenous glucose in normal and diabetic subjects. Diabetes 27: 327-333, 1978. 10.2337/diabetes.27.3.327

[45]

SCROCCHI LA, BROWN TJ, MACLUSKY N, BRUBAKER PL, AUERBACH AB, JOYNER AL, DRUCKER DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene. Nat Med 2: 1254-1258, 1996. 10.1038/nm1196-1254

[46]

SINHA MK, CARO JF: Clinical aspects of leptin. Vitam Horm 54: 1-30, 1998. 10.1016/s0083-6729(08)60919-x

[47]

SORIANO-GUILLEN L, BARRIOS V, LECHUGA-SANCHO A, CHOWEN JA, ARGENTE J: Response of circulating ghrelin levels to insulin therapyin children with newly diagnosed type 1 diabetes mellitus. Pediatr Res 55: 830-835, 2004. 10.1203/01.pdr.0000120679.92416.70

[48]

SPÅNGE A, EL-SALHY M: Large intestinal endocrine cells in non obese diabetic NOD-mice. J Diabetes Comp 2: 321-327, 1998. 10.1016/s1056-8727(98)00007-5

[49]

SUN Y, BUTTE NF, GARCIA JM, SMIT RG: Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology 149: 843-850, 2008. 10.1210/en.2007-0271

[50]

THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complication trial. Ann Intern Med 128: 517-523, 1998. 10.7326/0003-4819-128-7-199804010-00001

Showing 50 of 56 references

Metrics

33

Citations

56

References

Details

Published: Aug 17, 2011
Pages: 647-658

Authors

M

M. HUML

Charles University in Prague, Faculty of Medicine in Pilsen, Faculty Hospital, Department of Pediatrics, Pilsen, Czech Republic

Cite This Article

M. HUML, J. KOBR, K. Siala, et al. (2011). Gut Peptide Hormones and Pediatric Type 1 Diabetes Mellitus. Physiological Research, 647-658. https://doi.org/10.33549/physiolres.931995

Gut Peptide Hormones and Pediatric Type 1 Diabetes Mellitus

You May Also Like